Abstract:With the broad application of cancer immunotherapies such as immune checkpoint inhibitors in multiple cancer types, the immunological landscape in the tumor microenvironment (TME) has become enormously important for determining the optimal cancer treatment. Tumors can be immunologically divided into two categories: inflamed and non-inflamed based on the extent of immune cell infiltration and their activation status. In general, immunotherapies are preferable for the inflamed tumors than for non-inflamed tumors. Regulatory T cells (Tregs), an immunosuppressive subset of CD4 + T cells, play an essential role in maintaining self-tolerance and immunological homeostasis. In tumor immunity, Tregs compromise immune surveillance against cancer in healthy individuals and impair the antitumor immune response in tumor-bearing hosts. Tregs, therefore, accelerate immune evasion by tumor cells, leading to tumor development and progression in various types of cancer. Therefore, Tregs are considered to be a crucial therapeutic target for cancer immunotherapy. Abundant Tregs are observed in the TME in many types of cancer, both in inflamed and non-inflamed tumors. Diverse mechanisms of Treg accumulation, activation, and survival in the TME have been uncovered for different tumor types, indicating the importance of understanding the mechanism of Treg infiltration in each patient when selecting the optimal Treg-targeted therapy. Here, we review recent advances in the understanding of mechanisms leading to Treg abundance in the TME to optimize Treg-targeted therapy. Furthermore, in addition to the conventional strategies targeting cell surface molecules predominantly expressed by Tregs, reagents targeting molecules and signaling pathways specifically employed by Tregs for infiltration, activation, and survival in each tumor type are illustrated as novel Treg-targeted therapies. The effectiveness of immune precision therapy depends on conditions in the TME of each cancer patient.

Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies

Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells

Intratumoral regulatory T cells: markers, subsets and their impact on anti‐tumor immunity

Regulatory T cells in tumor immunity

Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?

Regulatory T cell-mediated immunosuppression orchestrated by cancer: towards an immuno-genomic paradigm for precision medicine

Targeting tumor-infiltrating tregs for improved antitumor responses

Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects

Regulatory T cells in cancer immunosuppression — implications for anticancer therapy

Regulatory T Cells: Barriers of Immune Infiltration Into the Tumor Microenvironment

Tumor Immune Checkpoints and Their Associated Inhibitors

Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy

Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting

Antibody-based Cancer Immunotherapy by Targeting Regulatory T Cells

Re-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies

Infiltrating treg reprogramming in the tumor immune microenvironment and its optimization for immunotherapy

Immunoregulatory T cells in tumor immunity

Lipid metabolism in tumor-infiltrating regulatory T cells: perspective to precision immunotherapy

Regulatory T‐cell development in the tumor microenvironment

Regulatory T Cells and Their Clinical Applications in Antitumor Immunotherapy

Regulatory T cells in immune checkpoint blockade antitumor therapy